Daiichi Sankyo Co Ltd
D4S
Company Profile
Business description
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2024, approximately one quarter of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its lead ADCs are Enhertu (HER2), Datroway (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu was first approved in the US in December 2019, and Datroway was first approved in January 2025.
Contact
3-5-1, Nihonbashi-Honcho
Chuo-ku
Tokyo103-8426
JPNT: +81 362251111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 March 2027
Employees
20,171
Stocks News & Analysis
stocks
Our view after Coles’ shares plunge
Shares dropped 8% after reporting results for the September 2026 quarter.
stocks
Cheap ASX share remains overlooked by the market
Fear outweighs fundamentals as ASX share reaffirms outlook.
stocks
Microsoft earnings: Azure accelerates, but investment returns remain the test
We now forecast mildly better revenue growth and EPS growth, alongside more intense near-term cash flow pressure.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,977.20 | 48.20 | -0.53% |
| CAC 40 | 7,975.56 | 6.14 | 0.08% |
| DAX 40 | 25,797.74 | 20.47 | -0.08% |
| Dow JONES (US) | 51,770.31 | 572.25 | -1.09% |
| FTSE 100 | 10,709.44 | 20.34 | -0.19% |
| HKSE | 23,393.32 | 98.90 | 0.42% |
| NASDAQ | 25,437.00 | 747.73 | -2.86% |
| Nikkei 225 | 63,081.86 | 208.25 | -0.33% |
| NZX 50 Index | 13,698.63 | 98.37 | -0.71% |
| S&P 500 | 7,580.07 | 140.32 | -1.82% |
| S&P/ASX 200 | 8,856.50 | 51.60 | -0.58% |
| SSE Composite Index | 3,638.03 | 39.01 | 1.08% |